| EPA064 | Broadly neutralizing HIV-1 antibodies as a PrEP modality among young sexual minority men: a conjoint experiment | E-poster | Immunotherapy (including broadly neutralizing antibodies) |
| EPA065 | Ex vivo HIV suppression in foreskin tissue after oral dosing of F/TDF and F/TAF in young African males | E-poster | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| EPA066 | Mode of interaction of CD4-CD4i antibody hybrids to HIV-1 envelope glycoproteins | E-poster | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| EPA067 | Small-molecule CD4-mimetic compounds expose vulnerable HIV-1 Env epitopes and contact the highly conserved aspartic acid 368 | E-poster | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| EPA068 | Metformin acts on HIV reservoirs to facilitate their recognition by the immune system | E-poster | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| EPA069 | Dual antiretroviral loaded nanoparticles for long-acting suppressive HIV therapy | E-poster | ARVs, small molecules and immunomodulating agents - pharmacodynamics and pharmacokinetics |
| EPA070 | High adaptive NK cell frequencies reduce the risk of developing coronary atherosclerotic plaque in cytomegalovirus infected people living with HIV | E-poster | HIV and co-morbidities |
| EPA071 | Scaling-up HPV testing for cervical cancer screening in WLHIV in Zambia | E-poster | HIV and co-morbidities |
| EPA072 | Association of HIV viremia with pro-inflammatory fatty acid signatures in pregnancy | E-poster | HIV and co-morbidities |
| EPA073 | MiRNAs as cardiovascular risk biomarkers in people living with HIV (PWH) | E-poster | HIV and co-morbidities |